Medical cannabis is booming: Cantourage Group SE reports record quarter in Q3 2024

Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01, www.cantourage.com), Europe's leading publicly traded cannabis company, generated revenues of EUR 13.2 million in the period from July 1 to September 30, 2024 (Q3 2024) (same period last year: EUR 5.9 million), setting a new record quarter in the company's history. Last month, the company announced that it had exceeded its total annual revenue for 2023 (EUR 23.6 million) with EUR 24.9 million in the period from January 1 to August 30, 2024. Another positive EBITDA in the range of EUR 0.9 million to EUR 1.1 million in Q3 2024 shows that Cantourage knows how to translate current developments in the European markets for medical cannabis into sustainable, profitable growth. Revenue of at least EUR 40million is expected for the full year 2024.

‍